SpringWorks Therapeutics Inc (SWTX)
44.86
+0.09
(+0.20%)
USD |
NASDAQ |
May 17, 16:00
44.86
0.00 (0.00%)
After-Hours: 20:00
SpringWorks Therapeutics Cash from Operations (Quarterly): -78.93M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -78.93M |
| December 31, 2023 | -62.70M |
| September 30, 2023 | -50.46M |
| June 30, 2023 | -47.81M |
| March 31, 2023 | -61.82M |
| December 31, 2022 | -54.20M |
| September 30, 2022 | -19.60M |
| June 30, 2022 | -39.07M |
| March 31, 2022 | -48.69M |
| December 31, 2021 | -46.32M |
| September 30, 2021 | -26.93M |
| Date | Value |
|---|---|
| June 30, 2021 | -33.53M |
| March 31, 2021 | -21.10M |
| December 31, 2020 | 15.07M |
| September 30, 2020 | -14.70M |
| June 30, 2020 | -16.16M |
| March 31, 2020 | -16.40M |
| December 31, 2019 | -16.06M |
| September 30, 2019 | -11.11M |
| June 30, 2019 | -13.09M |
| March 31, 2019 | -7.177M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-78.93M
Minimum
Mar 2024
15.07M
Maximum
Dec 2020
-33.18M
Average
-30.23M
Median
Cash from Operations (Quarterly) Benchmarks
| Geron Corp | -62.25M |
| Verastem Inc | -28.31M |
| Karyopharm Therapeutics Inc | -43.72M |
| Syndax Pharmaceuticals Inc | -83.55M |
| Arvinas Inc | -97.50M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 21.46M |
| Cash from Financing (Quarterly) | -0.552M |
| Free Cash Flow | -244.89M |
| Free Cash Flow Per Share (Quarterly) | -1.078 |
| Free Cash Flow to Equity (Quarterly) | -79.51M |
| Free Cash Flow Yield | -8.27% |